Steven Mah
Stock Analyst at TD Cowen
(2.12)
# 2,855
Out of 4,944 analysts
29
Total ratings
33.33%
Success rate
10.01%
Average return
Main Sectors:
Stocks Rated by Steven Mah
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TWST Twist Bioscience | Reiterates: Buy | $58 | $28.67 | +102.30% | 3 | Nov 26, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $28 → $31 | $25.29 | +22.58% | 2 | Nov 13, 2024 | |
| DNA Ginkgo Bioworks Holdings | Maintains: Outperform | $280 → $120 | $13.01 | +822.37% | 2 | Mar 1, 2024 | |
| RXRX Recursion Pharmaceuticals | Initiates: Market Perform | n/a | $5.60 | - | 1 | Jan 26, 2024 | |
| SDGR Schrödinger | Initiates: Outperform | $42 | $17.96 | +133.85% | 1 | Jan 26, 2024 | |
| ABCL AbCellera Biologics | Initiates: Outperform | n/a | $4.74 | - | 1 | Feb 28, 2023 | |
| OABI OmniAb | Initiates: Outperform | $10 | $2.06 | +386.62% | 1 | Feb 22, 2023 | |
| ABSI Absci | Upgrades: Outperform | n/a | $3.02 | - | 1 | Aug 12, 2022 | |
| CDXS Codexis | Maintains: Outperform | $39 → $21 | $3.48 | +503.45% | 2 | Jul 15, 2022 | |
| NTRA Natera | Maintains: Overweight | $150 → $155 | $156.57 | -1.00% | 4 | Jul 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $140 | $21.47 | +552.07% | 3 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $52 | $1.27 | +4,010.67% | 3 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $340 → $415 | $100.25 | +313.97% | 4 | Dec 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $168 → $250 | $26.29 | +850.93% | 1 | Jul 8, 2020 |
Twist Bioscience
Nov 26, 2024
Reiterates: Buy
Price Target: $58
Current: $28.67
Upside: +102.30%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $28 → $31
Current: $25.29
Upside: +22.58%
Ginkgo Bioworks Holdings
Mar 1, 2024
Maintains: Outperform
Price Target: $280 → $120
Current: $13.01
Upside: +822.37%
Recursion Pharmaceuticals
Jan 26, 2024
Initiates: Market Perform
Price Target: n/a
Current: $5.60
Upside: -
Schrödinger
Jan 26, 2024
Initiates: Outperform
Price Target: $42
Current: $17.96
Upside: +133.85%
AbCellera Biologics
Feb 28, 2023
Initiates: Outperform
Price Target: n/a
Current: $4.74
Upside: -
OmniAb
Feb 22, 2023
Initiates: Outperform
Price Target: $10
Current: $2.06
Upside: +386.62%
Absci
Aug 12, 2022
Upgrades: Outperform
Price Target: n/a
Current: $3.02
Upside: -
Codexis
Jul 15, 2022
Maintains: Outperform
Price Target: $39 → $21
Current: $3.48
Upside: +503.45%
Natera
Jul 6, 2021
Maintains: Overweight
Price Target: $150 → $155
Current: $156.57
Upside: -1.00%
Mar 5, 2021
Maintains: Overweight
Price Target: $135 → $140
Current: $21.47
Upside: +552.07%
Feb 11, 2021
Upgrades: Overweight
Price Target: $20 → $52
Current: $1.27
Upside: +4,010.67%
Dec 22, 2020
Upgrades: Overweight
Price Target: $340 → $415
Current: $100.25
Upside: +313.97%
Jul 8, 2020
Maintains: Overweight
Price Target: $168 → $250
Current: $26.29
Upside: +850.93%